Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2019-05-10
Last Posted Date
2024-11-19
Lead Sponsor
Norwegian University of Science and Technology
Target Recruit Count
112
Registration Number
NCT03944876
Locations
🇩🇪

Praxisklinik Ulmenhof, Hamburg, Germany

🇮🇹

Fondazione IRCCS Istituto Neurologico Carlo Besta (CBNI), Milano, Italy

🇳🇴

St Olavs Hospital, Trondheim, Norway

and more 2 locations

Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis

First Posted Date
2019-05-02
Last Posted Date
2024-12-20
Lead Sponsor
Johns Hopkins University
Target Recruit Count
90
Registration Number
NCT03935295
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Abobotulinumtoxina Efficacy in Post-Traumatic Headache

First Posted Date
2019-04-26
Last Posted Date
2019-04-26
Lead Sponsor
VA Greater Los Angeles Healthcare System
Target Recruit Count
40
Registration Number
NCT03928496
Locations
🇺🇸

VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

Botulinum Toxin A & Weekly Serial Casting in ABI Inpatients With Lower Extremity Spasticity

First Posted Date
2019-04-04
Last Posted Date
2023-09-28
Lead Sponsor
Hamilton Health Sciences Corporation
Registration Number
NCT03903653

Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2019-03-28
Last Posted Date
2019-03-28
Lead Sponsor
Medy-Tox
Target Recruit Count
168
Registration Number
NCT03894748
Locations
🇰🇷

The Catholic University of Korea, St. Paul's Hospital, Seoul, Dongdaemun-gu, Korea, Republic of

🇰🇷

Inha University Hospital, Incheon, Jung-gu, Korea, Republic of

🇰🇷

Kyung Hee University Hospital at Gangdong, Seoul, Kangdong-gu, Korea, Republic of

Occlusal Splints or Botulinum Toxin?

First Posted Date
2019-03-26
Last Posted Date
2019-03-26
Lead Sponsor
Ankara University
Target Recruit Count
73
Registration Number
NCT03891121
Locations
🇹🇷

Ankara University, Faculty of Dentistry, Ankara, Turkey

Botulinum Toxin A Injectable Solution in the Management of Bruxism: A Clinical Trial Study

Phase 2
Conditions
Interventions
First Posted Date
2019-02-01
Last Posted Date
2019-02-01
Lead Sponsor
Riyadh Colleges of Dentistry and Pharmacy
Target Recruit Count
20
Registration Number
NCT03827122
Locations
🇸🇦

Riyadh Elm University, Riyadh, Saudi Arabia

Hyperhydrosis Treatment Using Botulinum Toxin

Phase 4
Completed
Conditions
Interventions
First Posted Date
2019-01-25
Last Posted Date
2019-01-25
Lead Sponsor
St Joseph University, Beirut, Lebanon
Target Recruit Count
15
Registration Number
NCT03816046
Locations
🇱🇧

Hotel Dieu de France, Beirut, Lebanon

Botulinum Toxin in the Treatment of Gingival Smile

Phase 2
Completed
Conditions
Interventions
First Posted Date
2019-01-23
Last Posted Date
2019-06-05
Lead Sponsor
Universidade Ibirapuera
Target Recruit Count
20
Registration Number
NCT03812965
Locations
🇧🇷

Universidade Ibirapuera, São Paulo, SP, Brazil

© Copyright 2024. All Rights Reserved by MedPath